Royalty Pharma Statistics Share Statistics Royalty Pharma has 432.29M
shares outstanding. The number of shares has increased by 25.47%
in one year.
Shares Outstanding 432.29M Shares Change (YoY) 25.47% Shares Change (QoQ) 29.76% Owned by Institutions (%) 73.06% Shares Floating 379.85M Failed to Deliver (FTD) Shares 93,297 FTD / Avg. Volume 2.33%
Short Selling Information The latest short interest is 21.28M, so 4.92% of the outstanding
shares have been sold short.
Short Interest 21.28M Short % of Shares Out 4.92% Short % of Float 5% Short Ratio (days to cover) 4.16
Valuation Ratios The PE ratio is 13.24 and the forward
PE ratio is 6.95.
Royalty Pharma's PEG ratio is
-0.55.
PE Ratio 13.24 Forward PE 6.95 PS Ratio 5.03 Forward PS 4.8 PB Ratio 1.64 P/FCF Ratio 4.11 PEG Ratio -0.55
Financial Ratio History Enterprise Valuation Royalty Pharma has an Enterprise Value (EV) of 18.06B.
EV / Sales 7.98 EV / EBITDA 11.6 EV / EBIT 6.52 EV / FCF 6.52
Financial Position The company has a current ratio of 1.44,
with a Debt / Equity ratio of 1.1.
Current Ratio 1.44 Quick Ratio 1.44 Debt / Equity 1.1 Debt / EBITDA 4.89 Debt / FCF 2.75 Interest Coverage 5.73
Financial Efficiency Return on Equity is 12.37% and Return on Invested Capital is 7.19%.
Return on Equity 12.37% Return on Assets 4.71% Return on Invested Capital 7.19% Revenue Per Employee $30.18M Profits Per Employee $11.45M Employee Count 75 Asset Turnover 0.12 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 24.21% in the
last 52 weeks. The beta is 0.57, so Royalty Pharma's
price volatility has been higher than the market average.
Beta 0.57 52-Week Price Change 24.21% 50-Day Moving Average 36.3 200-Day Moving Average 33.03 Relative Strength Index (RSI) 41.84 Average Volume (20 Days) 4,000,830
Income Statement In the last 12 months, Royalty Pharma had revenue of 2.26B
and earned 858.98M
in profits. Earnings per share was 1.93.
Revenue 2.26B Gross Profit 2.26B Operating Income 1.29B Net Income 858.98M EBITDA 1.56B EBIT 1.56B Earnings Per Share (EPS) 1.93
Full Income Statement Balance Sheet The company has 929.03M in cash and 7.61B in
debt, giving a net cash position of -6.68B.
Cash & Cash Equivalents 929.03M Total Debt 7.61B Net Cash -6.68B Retained Earnings 2.85B Total Assets 18.32B Working Capital 313.71M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 2.77B
and capital expenditures 0, giving a free cash flow of 2.77B.
Operating Cash Flow 2.77B Capital Expenditures n/a Free Cash Flow 2.77B FCF Per Share 6.21
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of 57.1% and 37.95%.
Gross Margin 100% Operating Margin 57.1% Pretax Margin 58.79% Profit Margin 37.95% EBITDA Margin 68.76% EBIT Margin 57.1% FCF Margin 122.33%
Dividends & Yields RPRX pays an annual dividend of $1.08,
which amounts to a dividend yield of 2.39%.
Dividend Per Share $1.08 Dividend Yield 2.39% Dividend Growth (YoY) 4.76% Payout Ratio 47.16% Earnings Yield 7.55% FCF Yield 24.34%
Dividend Details Analyst Forecast The average price target for RPRX is $48,
which is 37% higher than the current price. The consensus rating is "Strong Buy".
Price Target $48 Price Target Difference 37% Analyst Consensus Strong Buy Analyst Count 2
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value $9.65 Lynch Upside -72.46% Graham Number 25.98 Graham Upside -25.86%
Scores Altman Z-Score 1.73 Piotroski F-Score 6
